

Form **8937**
(December 2017)
Department of the Treasury
Internal Revenue Service

Report of Organizational Actions Affecting Basis of Securities

OMB No. 1545-0123

▶ See separate instructions.

Part I Reporting Issuer

1 Issuer's name <u>Yumanity Therapeutics, Inc</u>		2 Issuer's employer identification number (EIN) <u>20-8436652</u>	
3 Name of contact for additional information <u>Keith A. Baker</u>	4 Telephone No. of contact <u>206-378-0400</u>	5 Email address of contact <u>kbaker@kineta.us</u>	
6 Number and street (or P.O. box if mail is not delivered to street address) of contact <u>219 Terry Avenue North, Suite 300</u>		7 City, town, or post office, state, and ZIP code of contact <u>Seattle, WA 98109</u>	
8 Date of action <u>12/19/2022</u>		9 Classification and description <u>Stock - Common</u>	
10 CUSIP number <u>98872L102</u>	11 Serial number(s)	12 Ticker symbol <u>YMTX</u>	13 Account number(s)

Part II Organizational Action Attach additional statements if needed. See back of form for additional questions.

14 Describe the organizational action and, if applicable, the date of the action or the date against which shareholders' ownership is measured for the action ▶ In 2022, Yumanity Therapeutics, Inc. distributed an aggregate amount of \$1.43 per share of common stock to its shareholders as follows:
\$1.43 per share on 12/19/2022.

15 Describe the quantitative effect of the organizational action on the basis of the security in the hands of a U.S. taxpayer as an adjustment per share or as a percentage of old basis ▶ Dividends paid in excess of the current accumulated earnings and profits ("E&P") of a corporation reduce the basis of the shares of the corporation pursuant to Internal Revenue Code ("IRC") Section 301(c)(2) and Section 316(a).

At this time, and based on reasonable assumptions of E&P, Yumanity Therapeutics, Inc. estimates that approximately 71% of the cash distribution will be treated as a taxable dividend distribution and 29% will be treated as a non-taxable return of capital or capital gain, depending upon shareholder basis.

16 Describe the calculation of the change in basis and the data that supports the calculation, such as the market values of securities and the valuation dates ▶ When a cash distribution (or other distribution of property) is made by a corporation, it is treated as a taxable dividend to the extent of the current and/or accumulated earnings and profits ("E&P") of that corporation on the date of the distribution or, in certain cases, at the end of the tax year in which the distribution was made. At this time, and based on reasonable assumptions of E&P, Yumanity Therapeutics, Inc. estimates that approximately 71% of the cash distribution will be treated as a taxable dividend distribution and 29% will be treated as a non-taxable return of capital or a capital gain, depending upon shareholder basis.

Pursuant to applicable Treasury regulations under Section 6045B, if these assumptions turn out to be incorrect, Yumanity Therapeutics, Inc. will file a corrected Form 8937 within 45 days of such determination.

For Paperwork Reduction Act Notice, see the separate Instructions.

Form **8937** (12-2017)

Part II Organizational Action (continued)

17 List the applicable Internal Revenue Code section(s) and subsection(s) upon which the tax treatment is based ▶ _____

Section 316 - Dividend defined

Section 317 - Property defined

Section 301(c) - Distribution of Property

Section 312 - Effect on earning and profits

Reg. Section 1.1502-33 - Earnings and profits (this section applies to taxpayers filing a consolidated federal corporate income tax return)

Other sections further defining adjustments to E&P that are not contained in Section 312

18 Can any resulting loss be recognized? ▶ This distribution will not create a loss.

19 Provide any other information necessary to implement the adjustment, such as the reportable tax year ▶ The adjustment to basis would be taken into account in the tax year of the shareholder during which the distribution was recieved (e.g. 2022 for calendar year taxpayers).

Sign Here

Under penalties of perjury, I declare that I have examined this return, including accompanying schedules and statements, and to the best of my knowledge and belief, it is true, correct, and complete. Declaration of preparer (other than officer) is based on all information of which preparer has any knowledge.

DocuSigned by:
 Signature ▶ Keith A. Baker Date ▶ 2/10/2023
 1E5422FAF0FB45E...
 Print your name ▶ Keith A. Baker Title ▶ CFO

Paid Preparer Use Only	Print/Type preparer's name	Preparer's signature	Date	Check <input type="checkbox"/> if self-employed	PTIN
	<u>RALPH ELDER</u>	<u>Ralph W. Elder</u>	<u>2/3/2023</u>		<u>P00242610</u>
	Firm's name ▶ <u>ANDERSEN TAX LLC</u>	Firm's address ▶ <u>1200 FIFTH AVENUE, SUITE 1600, SEATTLE, WA 98101</u>		Firm's EIN ▶ <u>33-1197384</u>	Phone no. <u>206-577-7880</u>